Precigen (NASDAQ:PGEN) Trading 7.5% Higher – Still a Buy?

Shares of Precigen, Inc. (NASDAQ:PGEN) were up 7.5% during trading on Friday . The company traded as high as $3.55 and last traded at $3.5250. Approximately 384,621 shares traded hands during mid-day trading, a decline of 91% from the average daily volume of 4,062,133 shares. The stock had previously closed at $3.28.

Analyst Ratings Changes

A number of analysts have recently issued reports on PGEN shares. Weiss Ratings restated a “sell (d-)” rating on shares of Precigen in a research report on Thursday, January 22nd. Zacks Research upgraded shares of Precigen from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 10th. Finally, Wall Street Zen lowered shares of Precigen from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $8.50.

Precigen Price Performance

The company has a 50-day moving average of $4.29 and a 200 day moving average of $4.05. The company has a debt-to-equity ratio of 2.22, a quick ratio of 3.95 and a current ratio of 4.04. The firm has a market cap of $1.24 billion, a P/E ratio of -2.53 and a beta of 1.10.

Insider Buying and Selling

In other Precigen news, Director Randal J. Kirk sold 1,900,036 shares of the business’s stock in a transaction dated Monday, December 22nd. The shares were sold at an average price of $4.18, for a total value of $7,942,150.48. Following the transaction, the director directly owned 341,189 shares in the company, valued at $1,426,170.02. The trade was a 84.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 47.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. Xponance LLC raised its position in Precigen by 21.3% in the 4th quarter. Xponance LLC now owns 14,191 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 2,496 shares during the last quarter. BNP Paribas Financial Markets grew its holdings in shares of Precigen by 6.1% during the third quarter. BNP Paribas Financial Markets now owns 51,796 shares of the biotechnology company’s stock worth $170,000 after purchasing an additional 2,993 shares during the last quarter. Composition Wealth LLC increased its stake in shares of Precigen by 16.5% in the fourth quarter. Composition Wealth LLC now owns 21,217 shares of the biotechnology company’s stock valued at $89,000 after buying an additional 3,000 shares in the last quarter. Intech Investment Management LLC raised its holdings in shares of Precigen by 5.2% in the fourth quarter. Intech Investment Management LLC now owns 63,018 shares of the biotechnology company’s stock valued at $263,000 after buying an additional 3,137 shares during the last quarter. Finally, Strs Ohio raised its holdings in shares of Precigen by 6.8% in the third quarter. Strs Ohio now owns 50,400 shares of the biotechnology company’s stock valued at $166,000 after buying an additional 3,200 shares during the last quarter. Institutional investors own 33.51% of the company’s stock.

About Precigen

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.